Expect to See Tirzepatide on Home Med Lists
July 2022
You’ll see patients coming in on the new injectable tirzepatide (Mounjaro)...the first “twincretin” for type 2 diabetes.
Think of it as similar to a glucagon-like peptide-1 (GLP-1) agonist...but it’s also a glucose-dependent insulinotropic polypeptide (GIP) agonist. More twincretins are in the works.
Both hormones are secreted in the gut in response to food...so the dual mechanism doesn’t seem to increase risk of hypoglycemia.Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote